Baxter International Reports Q4 2025 Financial Results with Mixed Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 12 2026
0mins
Should l Buy BAX?
Source: Newsfilter
- Sales Growth Overview: Baxter International reported fourth-quarter sales from continuing operations of $2.97 billion, reflecting an 8% increase year-over-year, yet U.S. sales of $1.55 billion only grew by 3%, indicating a softening demand in the market that adversely affects overall performance.
- Adjusted EPS Decline: The adjusted earnings per share stood at $0.44, down 24% from the previous year, primarily due to an unfavorable product mix and non-recurring expenses, highlighting challenges in profitability that necessitate improved cost management.
- Board Refreshment: Baxter announced the appointment of Michael R. McDonnell to its board, replacing two outgoing directors, which reflects the company's ongoing efforts to optimize its governance structure aimed at enhancing decision-making efficiency and corporate transparency.
- Future Outlook: The company anticipates flat to 1% sales growth from continuing operations for 2026, with adjusted EPS guidance between $1.85 and $2.05, indicating a cautiously optimistic management outlook despite facing market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BAX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BAX
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
2 Buy
5 Hold
1 Sell
Hold
Current: 16.900
Low
15.00
Averages
22.13
High
30.00
Current: 16.900
Low
15.00
Averages
22.13
High
30.00
About BAX
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Baxter Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: Baxter (BAX) is set to release its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $0.31, reflecting a significant 43.6% year-over-year decline, which could negatively impact investor sentiment.
- Revenue Expectations Decline: The anticipated revenue for Q1 is $2.62 billion, down 0.4% year-over-year, indicating pressure on the company amidst competitive market conditions, potentially affecting future investment decisions.
- Historical Performance Review: Over the past two years, Baxter has beaten EPS and revenue estimates 63% of the time, although recent EPS estimates have seen no upward revisions and seven downward adjustments, raising concerns about its profitability outlook.
- Analyst Rating Changes: In the last three months, EPS estimates have not seen any upward revisions, while revenue estimates experienced two upward and three downward revisions, suggesting a cautious outlook from analysts regarding Baxter's future performance.
See More
Baxter Exceeds Expectations in Q1 2026 Financials, Shares Rise
- International Sales Growth: Baxter (BAX) reported $2.7 billion in revenue for Q1 2026, reflecting a ~3% YoY increase that surpassed consensus estimates by $80 million, with international sales contributing $1.3 billion and achieving ~12% YoY growth, indicating strong performance in global markets.
- U.S. Market Decline: Despite robust international results, U.S. sales fell to $1.4 billion, representing a ~4% YoY decline, a trend that persists even after excluding results from the divested Kidney Care business, highlighting challenges in the domestic market.
- Adjusted Earnings Per Share: The company's adjusted EPS stood at $0.36, beating estimates by $0.05, although this reflects a ~35% YoY decline primarily due to unfavorable comparisons to the prior year and rising costs related to tariffs and manufacturing, indicating pressure on cost management.
- Full-Year Outlook Reaffirmed: Baxter reaffirmed its full-year sales growth outlook of 0%-1% and adjusted EPS guidance of $1.85-$2.05, compared to the consensus of 1% growth and $1.91 EPS, demonstrating the company's confidence in its future performance.
See More
Baxter International Reports $15 Million Net Loss in Q1
- Financial Decline: Baxter International reported a net loss of $15 million in Q1, translating to a loss of $0.03 per share, compared to a net income of $126 million or $0.25 per share in the same quarter last year, indicating a significant decline in profitability.
- Adjusted Earnings Drop: Excluding items, adjusted income from continuing operations was $0.37 per share, down from $0.62 per share last year, reflecting challenges in cost control and revenue growth.
- Sales Growth Stagnation: Worldwide net sales grew 3% to $2.70 billion, but organic sales declined by 1%, indicating a growth bottleneck in core operations that may impact future market competitiveness.
- Cautious Future Outlook: The company projects adjusted earnings from continuing operations for fiscal 2026 to be in the range of $1.85 to $2.05 per share, with sales growth expected to be flat to 1%, reflecting a cautious stance on future performance that could affect investor confidence.
See More
O'Keefe Stevens Advisory Q1 2026 Investment Moves
- Portfolio Adjustment: In Q1 2026, O'Keefe Stevens Advisory sold its positions in Alibaba (BABA), Fannie Mae common, BMW (BMWKY), and Mercedes-Benz (MBGAF), reflecting a cautious outlook on market conditions that may impact these companies' stock performance.
- Position Closure: The fund also closed its position in Tri Pointe Homes (TPH) due to the announced sale of the business, which could lead to decreased liquidity for the company and affect its future financing capabilities.
- New Investment Initiatives: Conversely, O'Keefe Stevens Advisory initiated new positions in Baxter International (BAX) and Weyerhaeuser (WY), indicating confidence in the growth potential of these companies, which may provide new revenue streams for its portfolio.
- Increased Holdings: The fund further strengthened its position in Perrigo (PRGO), suggesting optimism regarding the company's competitive edge and future performance, potentially enhancing its market position within the relevant industry.
See More
O’Keefe Stevens Advisory Underperforms in Q1 2026 Amid Market Declines
- Market Underperformance: In Q1 2026, O’Keefe Stevens Advisory's portfolio underperformed against a broadly weaker market, with the S&P 500 declining by 4.3% and the Nasdaq Composite falling by 7.0%, indicating a challenging market environment.
- New Investment Position: The portfolio initiated a new position in Baxter International (NYSE:BAX) during Q1 2026, suggesting a positive outlook on the company's growth potential despite the overall market's weak performance.
- Exit Strategy: In the same quarter, the strategy exited positions in Tri Pointe Homes (NYSE:TPH) and Alibaba (NYSE:BABA), reflecting a cautious stance on these companies' prospects, possibly to mitigate further market risks.
- Financial Data Insights: Tri Pointe Homes reported a GAAP EPS of $0.08, missing expectations by $0.09, while its revenue of $507.89 million beat estimates by $12.22 million, indicating resilience in revenue but a need for improvement in profitability.
See More
Baxter Unveils Next-Gen Surgical Equipment at AORN
- Product Launch: Baxter showcased the AAT XR spine surgical table and Dynamo Series smart stretcher at the AORN Global Surgical Conference, aimed at enhancing surgical team efficiency and patient safety, with availability expected in the U.S. in the second half of 2026.
- Surgical Efficiency Improvement: The AAT XR is designed to rotate 180 degrees without removing the patient, featuring quick lock functions and a maximum weight capacity of 650 pounds, significantly reducing physical strain on operating room staff and optimizing surgical workflows.
- Smart Stretcher Innovation: The Dynamo Series smart stretcher addresses common challenges faced by care teams in high-pressure settings by reducing patient transfer needs and simplifying positioning, thereby lowering fall risks and improving patient comfort.
- Advanced Surgery Portfolio: Baxter also highlighted its extensive portfolio of hemostatic and sealing agents aimed at reducing bleeding-related complications and overall costs, further solidifying its market position in the surgical field.
See More
Baxter Scheduled to Announce Q1 Earnings Results
- Earnings Announcement Date: Baxter (BAX) is set to release its Q1 earnings on April 30 before market open, with a consensus EPS estimate of $0.31, reflecting a significant 43.6% year-over-year decline, which could negatively impact investor sentiment.
- Revenue Expectations Decline: The anticipated revenue for Q1 is $2.62 billion, down 0.4% year-over-year, indicating pressure on the company amidst competitive market conditions, potentially affecting future investment decisions.
- Historical Performance Review: Over the past two years, Baxter has beaten EPS and revenue estimates 63% of the time, although recent EPS estimates have seen no upward revisions and seven downward adjustments, raising concerns about its profitability outlook.
- Analyst Rating Changes: In the last three months, EPS estimates have not seen any upward revisions, while revenue estimates experienced two upward and three downward revisions, suggesting a cautious outlook from analysts regarding Baxter's future performance.
See More
Baxter Exceeds Expectations in Q1 2026 Financials, Shares Rise
- International Sales Growth: Baxter (BAX) reported $2.7 billion in revenue for Q1 2026, reflecting a ~3% YoY increase that surpassed consensus estimates by $80 million, with international sales contributing $1.3 billion and achieving ~12% YoY growth, indicating strong performance in global markets.
- U.S. Market Decline: Despite robust international results, U.S. sales fell to $1.4 billion, representing a ~4% YoY decline, a trend that persists even after excluding results from the divested Kidney Care business, highlighting challenges in the domestic market.
- Adjusted Earnings Per Share: The company's adjusted EPS stood at $0.36, beating estimates by $0.05, although this reflects a ~35% YoY decline primarily due to unfavorable comparisons to the prior year and rising costs related to tariffs and manufacturing, indicating pressure on cost management.
- Full-Year Outlook Reaffirmed: Baxter reaffirmed its full-year sales growth outlook of 0%-1% and adjusted EPS guidance of $1.85-$2.05, compared to the consensus of 1% growth and $1.91 EPS, demonstrating the company's confidence in its future performance.
See More
Baxter International Reports $15 Million Net Loss in Q1
- Financial Decline: Baxter International reported a net loss of $15 million in Q1, translating to a loss of $0.03 per share, compared to a net income of $126 million or $0.25 per share in the same quarter last year, indicating a significant decline in profitability.
- Adjusted Earnings Drop: Excluding items, adjusted income from continuing operations was $0.37 per share, down from $0.62 per share last year, reflecting challenges in cost control and revenue growth.
- Sales Growth Stagnation: Worldwide net sales grew 3% to $2.70 billion, but organic sales declined by 1%, indicating a growth bottleneck in core operations that may impact future market competitiveness.
- Cautious Future Outlook: The company projects adjusted earnings from continuing operations for fiscal 2026 to be in the range of $1.85 to $2.05 per share, with sales growth expected to be flat to 1%, reflecting a cautious stance on future performance that could affect investor confidence.
See More
O'Keefe Stevens Advisory Q1 2026 Investment Moves
- Portfolio Adjustment: In Q1 2026, O'Keefe Stevens Advisory sold its positions in Alibaba (BABA), Fannie Mae common, BMW (BMWKY), and Mercedes-Benz (MBGAF), reflecting a cautious outlook on market conditions that may impact these companies' stock performance.
- Position Closure: The fund also closed its position in Tri Pointe Homes (TPH) due to the announced sale of the business, which could lead to decreased liquidity for the company and affect its future financing capabilities.
- New Investment Initiatives: Conversely, O'Keefe Stevens Advisory initiated new positions in Baxter International (BAX) and Weyerhaeuser (WY), indicating confidence in the growth potential of these companies, which may provide new revenue streams for its portfolio.
- Increased Holdings: The fund further strengthened its position in Perrigo (PRGO), suggesting optimism regarding the company's competitive edge and future performance, potentially enhancing its market position within the relevant industry.
See More
O’Keefe Stevens Advisory Underperforms in Q1 2026 Amid Market Declines
- Market Underperformance: In Q1 2026, O’Keefe Stevens Advisory's portfolio underperformed against a broadly weaker market, with the S&P 500 declining by 4.3% and the Nasdaq Composite falling by 7.0%, indicating a challenging market environment.
- New Investment Position: The portfolio initiated a new position in Baxter International (NYSE:BAX) during Q1 2026, suggesting a positive outlook on the company's growth potential despite the overall market's weak performance.
- Exit Strategy: In the same quarter, the strategy exited positions in Tri Pointe Homes (NYSE:TPH) and Alibaba (NYSE:BABA), reflecting a cautious stance on these companies' prospects, possibly to mitigate further market risks.
- Financial Data Insights: Tri Pointe Homes reported a GAAP EPS of $0.08, missing expectations by $0.09, while its revenue of $507.89 million beat estimates by $12.22 million, indicating resilience in revenue but a need for improvement in profitability.
See More
Baxter Unveils Next-Gen Surgical Equipment at AORN
- Product Launch: Baxter showcased the AAT XR spine surgical table and Dynamo Series smart stretcher at the AORN Global Surgical Conference, aimed at enhancing surgical team efficiency and patient safety, with availability expected in the U.S. in the second half of 2026.
- Surgical Efficiency Improvement: The AAT XR is designed to rotate 180 degrees without removing the patient, featuring quick lock functions and a maximum weight capacity of 650 pounds, significantly reducing physical strain on operating room staff and optimizing surgical workflows.
- Smart Stretcher Innovation: The Dynamo Series smart stretcher addresses common challenges faced by care teams in high-pressure settings by reducing patient transfer needs and simplifying positioning, thereby lowering fall risks and improving patient comfort.
- Advanced Surgery Portfolio: Baxter also highlighted its extensive portfolio of hemostatic and sealing agents aimed at reducing bleeding-related complications and overall costs, further solidifying its market position in the surgical field.
See More
